Surgery News

CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.

Editor’s Note: This is part three of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .

Editor’s Note: This is part two of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy.

Editor’s Note: This is part one of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .

Among patients with obesity undergoing bariatric surgery, the proportion taking a GLP-1 receptor agonist in the year before their procedure rose sharply between 2018 and 2023, researchers reported.

Allopathic vs. osteopathic medical education does not impact a surgeon’s clinical outcomes, according to data published in JAMA Surgery.

At current prices, bariatric surgery was more cost-effective than GLP-1 receptor agonists for treatment of obesity, researchers reported at the American College of Surgeons Clinical Congress.

In this Healio video exclusive, Sana M. Al-Khatib, MD, professor of medicine at Duke University School of Medicine, discusses barriers to developing cardiovascular digital health solutions for women.

A nonselective extracorporeal blood purifier connected to the cardiopulmonary bypass circuit during nonemergent cardiac surgery may help reduce post-surgical AKI, data show.